About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Hormone Receptor-Positive Advanced Breast Cancer: Case 3: Treatment with CDK4/6 Inhibitors
By
Cleveland Clinic Taussig Cancer Institute
FEATURING
Jame Abraham
,
Richard S. Finn
,
Maura N. Dickler
December 12, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:15
Novartis Oncology
CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…
Feat.
G. Hortobagyi
Featured Video
22:25
Novartis Oncology
The Importance of Dosing and Patient Adherence in HR+/HER2- mBC
Feat.
N. McAndrew
Related Content
AUTOPLAY
ON
11:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …
Feat.
P. Tarantino
28:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
17:39
Yale School of Medicine
2023 Menopause Update
Feat.
M. Minkin
13:03
Novartis Oncology
CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…
Feat.
D. Slamon
24:36
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
Feat.
H. Rugo,
J. O'Shaughnessy
23:58
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
17:04
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…
Feat.
G. Hortobagyi
03:05
ecancer
ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…
Feat.
D. Slamon
53:42
PleXus Communications
Managing Woman's Health in Menopause: Evolving Approaches for t…
Feat.
J. Simon,
T. Iyer,
A. Fiffick,
M. Minkin
08:38
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Utility of Ki67 in Guiding Adjuvant Abema…
Feat.
R. Patel
18:49
Yale School of Medicine
Menopause and Hot Flashes: What Medications are Available?
Feat.
M. Minkin
22:29
ESMO 2022 Conference Coverage
ESMO 2022 on Adjuvant Endocrine Therapy for BC: Who Needs More Than …
Feat.
E. de Azambuja
06:57
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ESR1 Mutational Landscape and Impact of C…
Feat.
A. Medford
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
06:47
UCSF School of Medicine
Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…
Feat.
H. Kang
03:32
UCSF School of Medicine
Management of Abemaciclib-Related Diarrhea in HR+/HER2- eBC
Feat.
S. Donahue
26:28
2023 West Oncology Conference
Antibody Drug Conjugates for Breast Cancer: The End of Chemotherapy?
Feat.
L. Schwartzberg
